About: Validation of neuromuscular blocking agent use in acute respiratory distress syndrome: a meta-analysis of randomized trials

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Validation of neuromuscular blocking agent use in acute respiratory distress syndrome: a meta-analysis of randomized trials Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Validation of neuromuscular blocking agent use in acute respiratory distress syndrome: a meta-analysis of randomized trials
Creator	Yang, Yi Qiu, Haibo Xie, Jianfeng Sun, Qin Chang, Wei Peng, Fei
source	PMC
abstract	BACKGROUND: We aimed to synthesize up-to-date trials to validate the effects of neuromuscular blocking agent (NMBA) use in patients with moderate-to-severe acute respiratory distress syndrome (ARDS). METHODS: Several databases including PubMed, EMBASE, Web of Science, and Cochrane Central Register were searched up to November 14, 2019. All randomized trials investigating the use of NMBAs in patients with moderate-to-severe ARDS and reporting mortality data were included in the meta-analysis. The primary outcome was mortality, and the secondary outcomes were clinical outcomes, including respiratory physiological parameters, incidence of barotrauma, ICU-free days, and ventilation-free days. RESULTS: A total of 7 trials enrolling 1598 patients were finally included in this meta-analysis. The results revealed that the use of NMBAs in moderate-to-severe ARDS could significantly decrease the mortality truncated to day 28 (RR 0.74, 95% CI 0.56 to 0.98, P = 0.03) and day 90 (RR 0.77, 95% CI 0.60 to 0.99, P = 0.04). NMBA use could significantly decrease the incidence of barotrauma (RR 0.56, 95% CI 0.36 to 0.87, P = 0.009). No significant difference was observed in ICU-free days or ventilation-free days between the NMBA and control groups. CONCLUSION: The use of NMBAs could significantly decrease mortality in moderate-to-severe ARDS patients and decrease the incidence of barotrauma during mechanical ventilation. However, more large-scale randomized trials are needed to further validate the effect of NMBA use in ARDS.
has issue date	2020-02-17(xsd:dateTime)
bibo:doi	10.1186/s13054-020-2765-2
bibo:pmid	32066488
has license	cc-by
sha1sum (hex)	d6383dad32d5b375938a5adede9d482aa5174e98
schema:url	https://doi.org/10.1186/s13054-020-2765-2
resource representing a document's title	Validation of neuromuscular blocking agent use in acute respiratory distress syndrome: a meta-analysis of randomized trials
has PubMed Central identifier	PMC7027110
has PubMed identifier	32066488
schema:publication	Crit Care
resource representing a document's body	covid:d6383dad32d5b375938a5adede9d482aa5174e98#body_text
is schema:about of	named entity 'EMBASE' named entity 'physiological parameters' named entity 'barotrauma' named entity 'acute respiratory distress syndrome' named entity 'refractory' named entity 'control groups' named entity 'meta-analysis' named entity 'meta-analysis' named entity 'categorical variable' named entity 'magic bullet' named entity 'diaphragm' named entity 'tidal volume' named entity 'Web of Science' named entity 'sample size' named entity 'control group' named entity 'confounding factor' named entity 'VILI' named entity 'intensive care unit' named entity 'ARDS' named entity 'refractory' named entity 'inflammatory response' named entity 'ARDS' named entity 'meta-analyses' named entity 'significant effect' named entity 'ARDS' named entity 'ICU' named entity 'Systematic Reviews' named entity 'PEEP' named entity 'sedation' named entity 'refractory' named entity 'PROSPERO' named entity 'epithelial' named entity 'ARDS' named entity 'Berlin' named entity 'statistical significance' named entity 'neuromuscular blocking agents' named entity 'respiratory rate' named entity 'statistical significance' named entity 'randomized control trial' named entity 'PEEP' named entity 'lung' named entity 'sedation' named entity 'randomized trial' named entity 'alveolar' named entity '1, 2' named entity 'metaanalysis' named entity 'Trial sequential analysis' named entity 'deep sedation' named entity 'ARDS' named entity 'carbon dioxide' named entity 'funnel plot' named entity 'ARDS' named entity 'deep sedation' named entity 'barotrauma' named entity '95% CI' named entity 'Cochrane' named entity 'ARDS' named entity 'chest imaging' named entity 'RCT' named entity 'control group' named entity 'ICU' named entity 'ARDS' named entity 'mechanical ventilation' named entity 'statistically significant' named entity 'Trial Sequential Analysis' named entity 'control group' named entity 'ventilator-induced lung injury' named entity 'TSA' named entity 'plateau pressure' named entity 'ARDS' named entity 'PEEP' named entity 'mechanical ventilation' named entity 'sedation' named entity 'physiological parameters' named entity 'plateau pressure' named entity 'systemic inflammatory'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software